# Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

> **NCT06532656** · PHASE2,PHASE3 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 75 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Lenacapavir
- **DRUG:** BIC/LEN FDC

## Key facts

- **NCT ID:** NCT06532656
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2028-02
- **Final completion:** 2028-08
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532656, "Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06532656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*